Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Jazz Pharmaceuticals plc Director's Dealing 2020

Nov 5, 2020

30751_dirs_2020-11-04_58fd5f66-7f5f-48d3-b223-04b72a6e1ee9.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2020-11-02

Reporting Person: ENRIGHT PATRICK G (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2020-11-02 Ordinary Shares M 9929 Acquired 30297 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2020-11-02 Phantom Stock $ M 9929 Disposed 2020-11-02 Ordinary Shares (9929) Direct

Footnotes

F1: On November 2, 2020, the Reporting Person's 9,929 phantom stock rights under the Issuer's Amended and Restated Directors Deferred Compensation Plan were settled for an equal number of the Issuer's ordinary shares.